This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Canadian Pharmaceutical Company Duchesnay Inc. Sets For International Expansion Following The US Approval Of Its Morning Sickness Medication Diclegis® By The FDA

Nausea and vomiting of pregnancy (NVP), commonly called morning sickness, affects between 70 to 85 percent of pregnant women with symptoms ranging from nausea to severe vomiting and retching that can last throughout the day. Some pregnant women may experience symptoms throughout their pregnancy. If left untreated, symptoms can sometimes progress to a potentially more serious condition called hyperemesis gravidarum (HG), which may require hospitalization. NVP can have a dramatic impact on the emotional and physical well-being of the expectant woman and her family.  NVP has also been shown to impose an economic burden on healthcare system and productivity lost.

ABOUT DUCHESNAY

Duchesnay Inc. is a privately held Canadian pharmaceutical company dedicated to improve the health and quality of life of pregnant women and to the advancement of maternal-fetal medicine and scientific research to reduce the risk of birth defects. Duchesnay develops safe and effective pharmacological solutions for use during pregnancy and breastfeeding. For more information, visit www.duchesnay.com.

SOURCE Duchesnay inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 17,841.98 -86.22 -0.48%
S&P 500 2,080.15 -9.31 -0.45%
NASDAQ 4,919.6440 -19.6830 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs